Prexasertib in Combination With Mitoxantrone, Etoposide and Cytarabine (MEC) in Relapsed/Refractory Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) - a Phase I Trial
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2019
Price : $35 *
At a glance
- Drugs Prexasertib (Primary) ; Cytarabine; Etoposide; Mitoxantrone
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 10 Jun 2019 Status changed from recruiting to discontinued.
- 24 Jan 2019 Status changed from not yet recruiting to recruiting.
- 17 Nov 2018 New trial record